References in periodicals archive ?
A review of the B-Cell Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
B-cell leukemia was intermediate-sized to large with open chromatin, variable numbers of inconspicuous nucleoli, and slightly irregular nuclear membranes associated with a high mitotic rate (ranging from 19 up to 160 mitoses per 10/HPF, with an average of 62 mitoses/10 HPF).
Grupp's research builds on his ongoing collaboration with Penn scientists who originally developed the modified T cells as a treatment for B-cell leukemias.
The company is advancing multiple XmAb([R]) antibody drug candidates into the clinic, led by anti-CD30 candidate XmAb([R])2513 in a Phase I clinical trial for the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma, and anti-CD19 candidate XmAb([R])5574 in pre-clinical development for the treatment for non-Hodgkin lymphoma and B-cell leukemia.
The company is advancing multiple XmAb([R]) antibody drug candidates into the clinic, led by anti-CD30 candidate XmAb([R])2513 in a Phase 1 clinical trial for the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma, and anti-CD19 candidate XmAb([R])5574 in pre-clinical development for the treatment for non-Hodgkin lymphoma and B-cell leukemia.
The company is advancing multiple XmAb[R] antibody drug candidates into the clinic, led by anti-CD30 candidate XmAb[R]2513 in a Phase I clinical trial for the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma, and anti-CD19 candidate XmAb[R]5574 in pre-clinical development for the treatment for non-Hodgkin lymphoma and B-cell leukemia.
Additional results demonstrated DXL625 more potently induced apoptosis (cell suicide) in B-cell lymphoma cells, B-cell leukemia (Hairy Cells) as well as discovering greater killing potency than Rituxan[R] in cell lines of both moderate and low expressors of CD20.
Rituximab is used in the treatment of B-cell non-Hodgkin's lymphoma, B-cell leukemia and rheumatoid arthritis.
Native ricin A chain coupled to tumor-specific monoclonal antibodies has been used as an immunotoxin to treat patients with B-cell leukemia and lymphoma.
Full browser ?